Results

1–10 of 36 results for Faricimab

A Phase I Study to Evaluate the Tie2 Agonist RO7446603, Alone or in Combination With Aflibercept orFaricimab, in Diabetic Macular Edema
Jeremiah Brown, MD, MS, FASRS
Annual Meeting Talks
2025
Update on Faricimab for DME: New Clinical Features of Eyes in the RHONE-X Long-Term Extension Study
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2025
Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the United States
Andres Emanuelli, MD
Annual Meeting Talks
2025
Volumetric Analysis of Hard Exudates on Optical Coherence Tomography: Biomarker Results of Faricimab vs Aflibercept From Phase 3 YOSEMITE/RHINE
Murtaza K Adam, MD
Annual Meeting Talks
2025
Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Emmanuel Chang, MD PhD FACS FASRS
Annual Meeting Talks
2023
Early Treatment Patterns and Outcomes in Patients With Neovascular Age-Related Macular Degeneration Initiating Faricimab: The FARETINA-AMD Study
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2023
Faricimab Rapidly Improves Fluid Parameters in Patients With nAMD
Nikolas JS London, MD, FACS, FASRS
Annual Meeting Talks
2023
Early Treatment Patterns and Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab: FARETINA-DME Study
Durga Borkar, MD
Annual Meeting Talks
2023
Time to Retinal Fluid Control With Faricimab vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2023
Faricimab Causes Rapid and Sustained Intraocular Suppression of Ang-2 and VEGF-A for Up to 16 Weeks in nAMD and DME
Rajeev H. Muni, MD, MSC, FRCS(C), FASRS
Annual Meeting Talks
2023